NO333619B1 - Transepikutan administrasjonsform for a behandle restless leg syndromet - Google Patents

Transepikutan administrasjonsform for a behandle restless leg syndromet Download PDF

Info

Publication number: NO333619B1
Authority: NO; Norway
Prior art keywords: stated; tds; acrylate; silicone; naphthol
Prior art date: 2002-05-06

Application number

NO20045240A

Other languages

English (en)

Norwegian (no)

Other versions

NO20045240L (no

Inventor

Thomas Lauterbach

Erwin Schollmayer

Original Assignee

Ucb Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-06

Filing date

2004-11-30

Publication date

2013-07-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29285132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO333619(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-11-30 Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh

2004-11-30 Publication of NO20045240L publication Critical patent/NO20045240L/no

2013-07-22 Publication of NO333619B1 publication Critical patent/NO333619B1/no

Links

208000005793 Restless legs syndrome Diseases 0.000 title claims abstract description 30
238000011282 treatment Methods 0.000 claims abstract description 38
230000001225 therapeutic effect Effects 0.000 claims abstract description 33
239000000902 placebo Substances 0.000 claims abstract description 21
229940068196 placebo Drugs 0.000 claims abstract description 21
229920001296 polysiloxane Polymers 0.000 claims abstract description 18
230000006872 improvement Effects 0.000 claims abstract description 14
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims abstract description 7
239000013543 active substance Substances 0.000 claims description 35
229960003179 rotigotine Drugs 0.000 claims description 35
KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 35
239000003814 drug Substances 0.000 claims description 32
239000000853 adhesive Substances 0.000 claims description 30
230000001070 adhesive effect Effects 0.000 claims description 30
239000011159 matrix material Substances 0.000 claims description 28
229940079593 drug Drugs 0.000 claims description 26
KFQYTPMOWPVWEJ-UHFFFAOYSA-N 6-{propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1CC2=C(O)C=CC=C2CC1N(CCC)CCC1=CC=CS1 KFQYTPMOWPVWEJ-UHFFFAOYSA-N 0.000 claims description 23
239000000203 mixture Substances 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 14
239000013464 silicone adhesive Substances 0.000 claims description 13
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 9
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 9
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 8
229910052909 inorganic silicate Inorganic materials 0.000 claims description 8
235000014113 dietary fatty acids Nutrition 0.000 claims description 7
239000000194 fatty acid Substances 0.000 claims description 7
229930195729 fatty acid Natural products 0.000 claims description 7
150000001412 amines Chemical class 0.000 claims description 6
229920001577 copolymer Polymers 0.000 claims description 6
-1 fatty acid esters Chemical class 0.000 claims description 6
229920001477 hydrophilic polymer Polymers 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 5
239000012458 free base Substances 0.000 claims description 5
235000011187 glycerol Nutrition 0.000 claims description 5
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims description 4
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 4
239000002585 base Substances 0.000 claims description 4
150000004665 fatty acids Chemical class 0.000 claims description 4
229940055577 oleyl alcohol Drugs 0.000 claims description 4
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims description 4
239000002245 particle Substances 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
150000003505 terpenes Chemical class 0.000 claims description 4
235000007586 terpenes Nutrition 0.000 claims description 4
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 3
239000005977 Ethylene Substances 0.000 claims description 3
239000002202 Polyethylene glycol Substances 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
229920001451 polypropylene glycol Polymers 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
WDQMWEYDKDCEHT-UHFFFAOYSA-N 2-ethylhexyl 2-methylprop-2-enoate Chemical compound CCCCC(CC)COC(=O)C(C)=C WDQMWEYDKDCEHT-UHFFFAOYSA-N 0.000 claims description 2
OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 2
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical class CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 2
239000005642 Oleic acid Substances 0.000 claims description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 2
150000002191 fatty alcohols Chemical class 0.000 claims description 2
150000002314 glycerols Chemical class 0.000 claims description 2
VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 claims description 2
LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 claims description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 claims description 2
239000000178 monomer Substances 0.000 claims description 2
NZIDBRBFGPQCRY-UHFFFAOYSA-N octyl 2-methylprop-2-enoate Chemical compound CCCCCCCCOC(=O)C(C)=C NZIDBRBFGPQCRY-UHFFFAOYSA-N 0.000 claims description 2
229940065472 octyl acrylate Drugs 0.000 claims description 2
ANISOHQJBAQUQP-UHFFFAOYSA-N octyl prop-2-enoate Chemical compound CCCCCCCCOC(=O)C=C ANISOHQJBAQUQP-UHFFFAOYSA-N 0.000 claims description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
RPQRDASANLAFCM-UHFFFAOYSA-N oxiran-2-ylmethyl prop-2-enoate Chemical compound C=CC(=O)OCC1CO1 RPQRDASANLAFCM-UHFFFAOYSA-N 0.000 claims description 2
230000035699 permeability Effects 0.000 claims description 2
239000000654 additive Substances 0.000 claims 1
SCFQUKBBGYTJNC-UHFFFAOYSA-N heptyl prop-2-enoate Chemical compound CCCCCCCOC(=O)C=C SCFQUKBBGYTJNC-UHFFFAOYSA-N 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 3
208000012195 Reunion island Larsen syndrome Diseases 0.000 description 57
208000024891 symptom Diseases 0.000 description 32
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
230000000694 effects Effects 0.000 description 19
238000002560 therapeutic procedure Methods 0.000 description 19
239000000243 solution Substances 0.000 description 17
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 14
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 14
238000013461 design Methods 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
238000009097 single-agent therapy Methods 0.000 description 12
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 11
239000011505 plaster Substances 0.000 description 11
229960002896 clonidine Drugs 0.000 description 10
201000010099 disease Diseases 0.000 description 10
229960004502 levodopa Drugs 0.000 description 9
230000036470 plasma concentration Effects 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 8
239000003136 dopamine receptor stimulating agent Substances 0.000 description 8
229940100640 transdermal system Drugs 0.000 description 8
230000008901 benefit Effects 0.000 description 7
239000011248 coating agent Substances 0.000 description 7
238000000576 coating method Methods 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
238000011161 development Methods 0.000 description 7
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
229920006267 polyester film Polymers 0.000 description 6
206010038743 Restlessness Diseases 0.000 description 5
229940052760 dopamine agonists Drugs 0.000 description 5
CEXBONHIOKGWNU-NTISSMGPSA-N hydron;(6s)-6-[propyl(2-thiophen-2-ylethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol;chloride Chemical compound [Cl-].CCC[NH+]([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 CEXBONHIOKGWNU-NTISSMGPSA-N 0.000 description 5
230000007774 longterm Effects 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
238000012360 testing method Methods 0.000 description 5
208000035475 disorder Diseases 0.000 description 4
238000001035 drying Methods 0.000 description 4
206010016256 fatigue Diseases 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229920000058 polyacrylate Polymers 0.000 description 4
230000009467 reduction Effects 0.000 description 4
230000002829 reductive effect Effects 0.000 description 4
230000002787 reinforcement Effects 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
206010047700 Vomiting Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
239000000556 agonist Substances 0.000 description 3
230000003321 amplification Effects 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
208000002173 dizziness Diseases 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
206010022437 insomnia Diseases 0.000 description 3
230000008693 nausea Effects 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
208000035824 paresthesia Diseases 0.000 description 3
238000011458 pharmacological treatment Methods 0.000 description 3
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
229960003089 pramipexole Drugs 0.000 description 3
208000019116 sleep disease Diseases 0.000 description 3
230000003860 sleep quality Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
230000008673 vomiting Effects 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
229920003134 Eudragit® polymer Polymers 0.000 description 2
206010061224 Limb discomfort Diseases 0.000 description 2
208000018737 Parkinson disease Diseases 0.000 description 2
239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
208000001431 Psychomotor Agitation Diseases 0.000 description 2
206010040914 Skin reaction Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
238000007792 addition Methods 0.000 description 2
229960004046 apomorphine Drugs 0.000 description 2
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
230000008859 change Effects 0.000 description 2
239000004205 dimethyl polysiloxane Substances 0.000 description 2
230000004907 flux Effects 0.000 description 2
235000013305 food Nutrition 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000002050 international nonproprietary name Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000011866 long-term treatment Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000000034 method Methods 0.000 description 2
230000003557 neuropsychological effect Effects 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
238000004806 packaging method and process Methods 0.000 description 2
230000000737 periodic effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 2
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
231100000430 skin reaction Toxicity 0.000 description 2
230000035483 skin reaction Effects 0.000 description 2
208000022925 sleep disturbance Diseases 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000012935 Averaging Methods 0.000 description 1
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 1
101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
239000011627 DL-alpha-tocopherol Substances 0.000 description 1
235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
229940081615 DOPA decarboxylase inhibitor Drugs 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
206010063914 Multimorbidity Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
229920003082 Povidone K 90 Polymers 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
208000020764 Sensation disease Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
239000004115 Sodium Silicate Substances 0.000 description 1
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
230000003416 augmentation Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960002802 bromocriptine Drugs 0.000 description 1
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
229960004596 cabergoline Drugs 0.000 description 1
FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
229960000623 carbamazepine Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
ZJQPLBFKBQYYIO-UHFFFAOYSA-N dodecasodium;trisilicate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] ZJQPLBFKBQYYIO-UHFFFAOYSA-N 0.000 description 1
239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000026781 habituation Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
239000007970 homogeneous dispersion Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000005555 hypertensive agent Substances 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
208000036260 idiopathic disease Diseases 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000000185 intracerebroventricular administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000007803 itching Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229960003587 lisuride Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000003604 miotic agent Substances 0.000 description 1
230000036651 mood Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
231100000344 non-irritating Toxicity 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000011347 resin Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
229960001879 ropinirole Drugs 0.000 description 1
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
238000012154 short term therapy Methods 0.000 description 1
229920002050 silicone resin Polymers 0.000 description 1
230000037321 sleepiness Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
235000019795 sodium metasilicate Nutrition 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 1
229910052911 sodium silicate Inorganic materials 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000003867 tiredness Effects 0.000 description 1
208000016255 tiredness Diseases 0.000 description 1
229960000984 tocofersolan Drugs 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20045240A 2002-05-06 2004-11-30 Transepikutan administrasjonsform for a behandle restless leg syndromet NO333619B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10220230A DE10220230A1 (de)	2002-05-06	2002-05-06	Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
PCT/EP2003/004685 WO2003092677A1 (de)	2002-05-06	2003-05-05	Transepikutane darreichungsform zur behandlung des restless leg syndroms

Publications (2)

Publication Number	Publication Date
NO20045240L NO20045240L (no)	2004-11-30
NO333619B1 true NO333619B1 (no)	2013-07-22

Family

ID=29285132

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20045240A NO333619B1 (no)	2002-05-06	2004-11-30	Transepikutan administrasjonsform for a behandle restless leg syndromet

Country Status (23)

Country	Link
EP (1)	EP1501499B1 (pl)
JP (2)	JP5253707B2 (pl)
KR (1)	KR20040104697A (pl)
CN (1)	CN100396281C (pl)
AT (1)	ATE387912T1 (pl)
AU (1)	AU2003233233B2 (pl)
BR (1)	BR0309837A (pl)
CA (2)	CA2483120C (pl)
CY (1)	CY1107452T1 (pl)
DE (2)	DE10220230A1 (pl)
DK (1)	DK1501499T3 (pl)
ES (1)	ES2301795T3 (pl)
IL (2)	IL164861A0 (pl)
MX (1)	MXPA04010687A (pl)
NO (1)	NO333619B1 (pl)
NZ (1)	NZ536533A (pl)
PL (1)	PL218549B1 (pl)
PT (1)	PT1501499E (pl)
RU (1)	RU2301063C9 (pl)
SI (1)	SI1501499T1 (pl)
UA (1)	UA81625C2 (pl)
WO (1)	WO2003092677A1 (pl)
ZA (1)	ZA200408862B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10041478A1 (de)	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
DE10359528A1 (de)	2003-12-18	2005-07-28	Schwarz Pharma Ag	(S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum
MY149152A (en)	2006-05-08	2013-07-15	Teikoku Seiyaku Kk	Percutaneous absorption preparations of antimentia drugs
TWI392670B (zh)	2006-06-22	2013-04-11	Ucb Pharma Gmbh	經取代的２-胺基萘滿之於製造用於預防、減緩及／或治療各種類型疼痛之藥物上的用途
EP1987815A1 (en) *	2007-05-04	2008-11-05	Schwarz Pharma Ag	Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
NZ584363A (en)	2007-11-28	2012-11-30	Ucb Pharma Gmbh	Drug formulations of Rotigotine which comprise the thermodynamically stable polymorphic form 2
US9155725B2 (en)	2008-02-27	2015-10-13	Hisamitsu Pharmaceutical Co., Inc.	Adhesive skin patch and packaged product
EP2255809B1 (en) *	2008-02-27	2017-08-23	Hisamitsu Pharmaceutical Co., Inc.	Medicated patch
EP2201941A1 (de)	2008-12-29	2010-06-30	UCB Pharma GmbH	Pflaster-Herstellungstechnologie
EP2281559A1 (en)	2009-06-26	2011-02-09	UCB Pharma GmbH	Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis
LT3257504T (lt)	2009-12-22	2024-08-26	UCB Biopharma SRL	Polivinilpirolidonas, skirtas nekristalinės formos kietos rotigotino dispersijos stabilizavimui
US8729306B2 (en)	2010-02-05	2014-05-20	Ucb Pharma Gmbh	Process for the preparation of nitrogen substituted aminotetralins derivatives
BR112012029944A2 (pt)	2010-06-25	2019-09-24	Ucb Pharma Gmbh	processo para preparação de derivados de aminotetralinas substituídas com nitrogênio
EP2559435A1 (en)	2011-08-19	2013-02-20	UCB Pharma GmbH	Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
WO2013075823A1 (en)	2011-11-22	2013-05-30	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermal therapeutic system comprising rotigotine and crystallization inhibitor
DE102012013439A1 (de)	2012-07-03	2014-01-23	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System umfassend Rotigotin und Kristallisationsinhibitor
DE102012013421A1 (de)	2012-07-03	2014-01-09	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Transdermales therapeutisches System (TTS) mit Rotigotin
MX2015000049A (es) *	2012-07-05	2015-04-08	Sk Chemicals Co Ltd	Preparacion absorbible transdermicamente que contiene rotigotina.
EP2870963A4 (en) *	2012-07-06	2016-03-09	Sk Chemicals Co Ltd	PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING
TW201431570A (zh)	2012-11-22	2014-08-16	Ucb Pharma Gmbh	用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP6726096B2 (ja)	2013-07-03	2020-07-22	エルテーエスローマンテラピー−システメアーゲー	電子部品を有する経皮治療システム
WO2015129527A1 (ja)	2014-02-27	2015-09-03	株式会社メドレックス	プラミペキソールを含有する神経変性疾患の治療用貼付剤
CA2948219C (en)	2014-05-20	2023-04-04	Lts Lohmann Therapie-Systeme Ag	Method for adjusting the release of active agent in a transdermal delivery system
CN106456566B (zh)	2014-05-20	2020-06-16	Lts勒曼治疗系统股份公司	含罗替戈汀的经皮递送系统
US11752110B2 (en)	2014-05-20	2023-09-12	Lts Lohmann Therapie-Systeme Ag	Transdermal delivery system including an interface mediator
JP6872675B1 (ja)	2019-06-14	2021-05-19	久光製薬株式会社	ロチゴチン含有貼付剤
ES2966170T3 (es)	2020-01-24	2024-04-18	Luye Pharma Switzerland Ag	Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5656286A (en) *	1988-03-04	1997-08-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5474783A (en) *	1988-03-04	1995-12-12	Noven Pharmaceuticals, Inc.	Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5232702A (en) *	1991-07-22	1993-08-03	Dow Corning Corporation	Silicone pressure sensitive adhesive compositons for transdermal drug delivery devices and related medical devices
DE4238223C1 (de) *	1992-11-12	1994-05-26	Lohmann Therapie Syst Lts	Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung
US5482988A (en) *	1994-01-14	1996-01-09	Dow Corning Corporation	Hot-melt silicone pressure sensitive adhesive with siloxylated polyether waxes as additives
IL116539A (en) *	1995-01-06	2002-02-10	Noven Pharma	Preparations given through the skin of unstable anti-acid drugs
FR2749514B1 (fr) *	1996-06-11	1998-08-07	Hoechst Marion Roussel	Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
DE19701619B4 (de) *	1997-01-17	2007-10-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verwendung von Pramipexol zur Behandlung des restless legs syndroms
DE19814084B4 (de) *	1998-03-30	2005-12-22	Lts Lohmann Therapie-Systeme Ag	D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19938823A1 (de) *	1999-08-19	2001-02-22	Boehringer Ingelheim Pharma	Medikamentöse Behandlung des Restless Leg Syndroms
DE19938825A1 (de) *	1999-08-19	2001-04-26	Boehringer Ingelheim Pharma	Wirkstoffkombination mit Clonidin
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
ATE246919T1 (de) *	2001-05-08	2003-08-15	Sanol Arznei Schwarz Gmbh	Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson
EP1256339B1 (en) *	2001-05-08	2003-10-15	Schwarz Pharma Ag	Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine

2002
- 2002-05-06 DE DE10220230A patent/DE10220230A1/de not_active Ceased
2003
- 2003-05-05 MX MXPA04010687A patent/MXPA04010687A/es active IP Right Grant
- 2003-05-05 UA UA20041109078A patent/UA81625C2/ru unknown
- 2003-05-05 JP JP2004500861A patent/JP5253707B2/ja not_active Expired - Lifetime
- 2003-05-05 KR KR10-2004-7017685A patent/KR20040104697A/ko not_active Ceased
- 2003-05-05 PL PL373276A patent/PL218549B1/pl unknown
- 2003-05-05 ES ES03727432T patent/ES2301795T3/es not_active Expired - Lifetime
- 2003-05-05 SI SI200331195T patent/SI1501499T1/sl unknown
- 2003-05-05 DK DK03727432T patent/DK1501499T3/da active
- 2003-05-05 AT AT03727432T patent/ATE387912T1/de active
- 2003-05-05 PT PT03727432T patent/PT1501499E/pt unknown
- 2003-05-05 CN CNB038160250A patent/CN100396281C/zh not_active Expired - Fee Related
- 2003-05-05 AU AU2003233233A patent/AU2003233233B2/en not_active Ceased
- 2003-05-05 IL IL16486103A patent/IL164861A0/xx unknown
- 2003-05-05 EP EP03727432A patent/EP1501499B1/de not_active Revoked
- 2003-05-05 WO PCT/EP2003/004685 patent/WO2003092677A1/de not_active Ceased
- 2003-05-05 RU RU2004131866/15A patent/RU2301063C9/ru active
- 2003-05-05 CA CA2483120A patent/CA2483120C/en not_active Expired - Fee Related
- 2003-05-05 DE DE50309318T patent/DE50309318D1/de not_active Expired - Lifetime
- 2003-05-05 CA CA2787384A patent/CA2787384A1/en not_active Abandoned
- 2003-05-05 NZ NZ536533A patent/NZ536533A/en not_active IP Right Cessation
- 2003-05-05 BR BR0309837-0A patent/BR0309837A/pt not_active Application Discontinuation
2004
- 2004-10-27 IL IL164861A patent/IL164861A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08862A patent/ZA200408862B/en unknown
- 2004-11-30 NO NO20045240A patent/NO333619B1/no not_active IP Right Cessation
2008
- 2008-05-02 CY CY20081100471T patent/CY1107452T1/el unknown
2010
- 2010-04-22 JP JP2010098924A patent/JP2010159302A/ja active Pending

Also Published As

Publication number	Publication date
IL164861A0 (en)	2005-12-18
PL373276A1 (pl)	2005-08-22
AU2003233233B2 (en)	2008-03-06
CY1107452T1 (el)	2012-12-19
KR20040104697A (ko)	2004-12-10
CA2787384A1 (en)	2003-11-13
AU2003233233A1 (en)	2003-11-17
CN100396281C (zh)	2008-06-25
ES2301795T3 (es)	2008-07-01
CA2483120A1 (en)	2003-11-13
DE50309318D1 (de)	2008-04-17
RU2004131866A (ru)	2005-06-10
PL218549B1 (pl)	2014-12-31
JP5253707B2 (ja)	2013-07-31
PT1501499E (pt)	2008-05-20
UA81625C2 (ru)	2008-01-25
IL164861A (en)	2011-06-30
CA2483120C (en)	2013-07-16
MXPA04010687A (es)	2005-06-08
ATE387912T1 (de)	2008-03-15
JP2005528413A (ja)	2005-09-22
RU2301063C2 (ru)	2007-06-20
JP2010159302A (ja)	2010-07-22
CN1665497A (zh)	2005-09-07
DK1501499T3 (da)	2008-06-23
HK1072541A1 (zh)	2005-09-02
ZA200408862B (en)	2005-09-28
SI1501499T1 (sl)	2008-06-30
EP1501499B1 (de)	2008-03-05
WO2003092677A1 (de)	2003-11-13
RU2301063C9 (ru)	2007-11-27
NO20045240L (no)	2004-11-30
BR0309837A (pt)	2005-03-01
DE10220230A1 (de)	2003-11-27
NZ536533A (en)	2010-02-26
EP1501499A1 (de)	2005-02-02

Legal Events

Date	Code	Title	Description
2021-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO333619B1 (no)	2013-07-22	Transepikutan administrasjonsform for a behandle restless leg syndromet
US20040048779A1 (en)	2004-03-11	Use of rotigotine for treating the restless leg syndrome
JP5026656B2 (ja)	2012-09-12	ロチゴチンの高い血漿レベルを誘導するパーキンソン氏病のための経皮吸収治療システム
KR100968293B1 (ko)	2010-07-07	파킨슨병의 치료를 위한 개선된 경피제제
AU2002310805A1 (en)	2003-05-01	Improved transdermal therapeutic system for the treatment of Parkinson's disease
NO329974B1 (no)	2011-01-31	Sammensetning for topisk applikasjon av metylfenidat, og anvendelse av metylfenidat i fremstillingen av et fleksibelt, endelig system for behandling av ADHD og ADD.
JP2005528413A5 (pl)	2006-02-16
JP6912122B2 (ja)	2021-07-28	経皮投与製剤
HK1072541B (en)	2008-06-27	Trans-epicutaneous administration form for treating restless leg syndrome
AU2005242160A1 (en)	2006-01-05	Improved transdermal therapeutic system for the treatment of Parkinson's Disease